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Background: Common genetic variants have been shown to modify BRCA1 penetrance. The aim of this study was
to validate these reports in a special cohort of Norwegian BRCA1 mutation carriers that were selected for their
extreme age of onset of disease.
Methods: The ten variants rs13387042, rs3803662, rs8170, rs9397435, rs700518, rs10046, rs3834129, rs1045485,
rs2363956 and rs16942 were selected to be tested on samples from our biobank. We selected female BRCA1
mutation carriers having had a diagnosis of breast or ovarian cancer below 40 years of age (young cancer group,
N = 40), and mutation carriers having had neither breast nor ovarian cancer above 60 years of age (i.e., old no
cancer group, N = 38). Relative risks and odd ratios of belonging to the young cancer versus old no cancer groups
were calculated as a function of having or not having the SNPs in question.
Results: Five of the ten variants were found to be significantly associated with early onset cancer. Some of the
variation between our results and those previously reported may be ascribed to stochastic effects in our limited
number of patient studies, and/or genetic drift in linkage disequilibrium in the genetically isolated Norwegian
population. This is in accordance with the understanding that the SNPs are markers in linkage disequilibrium with
their respective disease-causing genetic variants, and that this may vary between different populations.
Conclusions: The results confirmed associations previously reported, with the notion that the degree of association
may differ between other populations, which must be considered when discussing the clinical use of the
associations described.
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Mutations in the BRCA1 gene constitute a high life-time
risk of breast and ovarian cancer. Risk reducing
salpingo-oophorectomy over the age of 35 years is advo-
cated to reduce the risk of cancer and early death [1].
Breast cancer may be prevented by prophylactic mastec-
tomy and patient prognosis improved when breast can-
cer is detected early with mammography and MRI [2].
Because BRCA1-associated breast cancer has an early
onset, prophylactic mastectomy must be undertaken at
younger age to provide a maximum protective effect [3].
BRCA1-associated cancer is age-dependent, and whether
or not this is stochastic or influenced by other factors
(modifiers of penetrance) is a question that has not been* Correspondence: moller.pal@gmail.com
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creativecommons.org/publicdomain/zero/1.0/fully explored: Both stochastic elements and modifying fac-
tors may be instrumental in diseases causation. Modifying
factors may be genetic, environmental, or both. This study
was designed to validate previous reports of normal genetic
variants that contribute to modifying BRCA1 penetrance.
A number of normal single nucleotide polymorphisms
(SNPs) associated with breast cancer in the general
population have been demonstrated to modify the pene-
trance of BRCA1 [4–13]. We decided not to participate
in the initial studies of these modifiers of breast cancer
penetrance, and we now have one of the few sufficiently
large series of well-described BRCA1 mutation carriers
to validate the findings reported by others.
The aim of this study was to determine whether SNPs
reported to be associated with cancer risk in BRCA1
mutation carriers in other populations had the same as-
sociation in the Norwegian population.article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Selection of patients
All study subjects were demonstrated BRCA1 mutation
carriers at the outpatient Cancer Genetics Clinic, Oslo
University Hospital and the respective mutations were as
previously reported [14]. Two groups were selected for
analysis: Mutation carriers having had breast and/or
ovarian cancer under the age of 40 years, hereafter de-
scribed as the young cancer group, and mutation carriers
who were completely disease free until their 60th birth-
day, or older (the old no cancer group). If there were to
be significant associations between age at onset of can-
cer and the SNPs considered in our material, they
should be identified by comparing the extremes by this
approach. The study was approved by both the Ethical
review board (ref S02030) and the Norwegian Data
Inspectorate (ref 2001/2988-2). All genetic counseling
and testing was performed according to Norwegian law,
and all patients gave written informed consent. The
present report is one in a series to meet a request from
the Norwegian Parliament to report the results of our
studies into inherited breast and or ovarian cancer risk.
We did not discriminate between breast or ovarian can-
cer, as we have previously shown that there is no sib pair
concordance for breast and ovarian cancer in BRCA1
mutation carriers in our population [15]. Patients having
had prophylactic mastectomies under the age of 60 years
were excluded from the study, patients having had
prophylactic salpingo-oophorectomy, but not mastec-
tomy, were included in the old group. Power calculations
indicated that, if reasonable prevalence of the variant al-
leles for each of the modifiers tested, we would reach
significance if the OR > 2 or <0.5, and with 50 partici-
pants in both the young cancer and old no cancer
groups. Preliminary analyses on the number of women
having consented to participate, indicated that we would
reach significance by selecting affected women aged less
than 40 years and women unaffected at over 60 years as
mentioned previously.
Test panel/selection of SNPs
Not knowing the prevalence of the genetic variants in
question in Norway, nor their association with disease,
we selected the ten genetic variants reported to have the
highest association with early/late onset of breast cancer
among BRCA1 mutation carriers in 2011 when the study
was designed. The test panel consisted of nine single nu-
cleotide polymorphisms (SNPs) and one deletion shown
to be associated with cancer risk in BRCA1 mutation
carriers as shown in Table 1. For simplicity, we will in
this report refer to the deletion as a SNP. Seven of the
SNPs were reported to increase cancer risk [4–10] and
three were reported to decrease risk for breast cancer in
BRCA1-mutation carriers [11–13].Initially, we demonstrated the SNPs in the test panel
to be polymorphic in our population of healthy Norwegian
blood donors (N = 3000), and the rare SNP alleles had a
frequency > 5 % (data not shown). The disease-associated
alleles were defined as the minor or risk allele (from which
positive or negative associations with disease were
calculated), regardless of whether or not this was the least
common allele in our population.
Genotyping
Samples
Blood samples were obtained after informed consent
and stored at −20 °C (or −70 °C). DNA was extracted
from 200 μl of whole blood by using a Qiagen BioRobot
M48 Robotic Workstation, following the protocol of the
MagAttract DNA Blood Mini M48 kit (Qiagen, Hilden,
Germany).
Fragment design
Default Primer3 (http://bioinfo.ut.ee/primer3/, last ac-
cession date 03062014) parameters were applied when
designing primers used to amplify fragments around
each DNA variant, identified by the NCBI SNP reference
numbers (rs) [16]. A 42-bp artificial high melting do-
main, labeled with 6-FAM, was incorporated at one end
of the amplified target using a set of three primers in the
PCR setup [17].
PCR
The PCR reaction mixtures were as described by the
manufacturer (Life technologies Carlsbad CA) without
modification. Annealing temperatures are given in Add-
itional file 1.
Electrophoresis
We used cycling temperature capillary electrophoresis
(CTCE) to detect allelic variants as described previously
[16, 17].
Statistics
We confirmed that the prevalence of the SNPs in the
young cancer and old no cancer groups assessed to-
gether were all in Hardy–Weinberg equilibrium.
Since this was a one-sided study, we used Fishers’
exact to identify any significant association.
Results
The selection criteria applied to our data set revealed 40
patients in the young cancer group and 38 participants
in the old no cancer group, which was considered suffi-
cient to reveal any difference in the frequency of SNPs
between the two groups. Forty-seven (60 %) patients had
eight different founder mutations previously reported
[18], of whom 25 belonged to the young onset cancer
Table 1 Distribution of genotypes in the ten SNPs determined in BRCA1 mutation carriers with breast or ovarian cancer before
40 years of age (young cancer) and in carriers not having had breast or ovarian cancer before 60 years of age (old no cancer), and
with calculated RR and OR, and HR/OR from previous reports [according to references given in left column]
SNP Genotype Young cancer
(number of cases)
Old no cancer
(number of cases)
Reported risk ObservedRR
(95 % CI)
ObservedOR
(95 % CI)
Fishers’ exact
p – one sided
rs13387042 2q35 [4] GG 13 18 1 -
AA 9 9 HR 1.05 1.19 (0.64–2.22) 1.38 (0.43–4.45) 0.40
GA 17 11 HR 1.14 1.45 (0.87–2.41) 2.14 (0.76–6.06) 0.12
AA or GA 26 20 1.35 (0.83–2.19) 1.80 (0.72–4.52) 0.15
rs3803662 16q12 TOX3,
LOC643714 [5]
CC 18 26 1 -
TT 1 2 HR 1.24 0.81 (0.16–4.20) 0.72 (0.06–8.58) 0.65
CT 20 10 HR 1.11 1.63 (1.05–2.52) 2.89 (1.10–7.61) 0.03*
TT or CT 21 12 1.56 (1.00–2.41) 2.53 (1.00–6.40) 0.04*
rs8170 19p13 [6] GG 29 27 1 -
AA 0 1 HR 1.35 - - -
GA 11 10 HR 1.22 1.01 (0.63–1.63) 1.02 (0.38–2.80) 0.58
AA or GA 11 11 0.97 (0.59–1.57) 0.93 (0.35–2.50) 0.65
rs9397435 6q25 ESR1 [7] AA 32 34 1 -
GG 1 0 HR 1.37 2.06 (1.61–2.64) - -
AG 7 4 HR 1.31 1.31 (0.79–2.19) 1.86 (0.50–6.96) 0.27
GG or AG 8 4 1.38 (0.86–2.20) 2.13 (0.58–7.75) 0.20
rs700518 CYP19 [8] AA 12 14 1 -
GG 16 6 OR 2.81 1.58 (0.97–2.57) 3.11 (0.92–10.48) 0.06
AG 11 17 OR 1.41 0.85 (0.46–1.58) 0.75 (0.26–2.23) 0.41
GG or AG 27 23 1.17 (0.72–1.91) 1.37 (0.53–3.54) 0.34
rs10046 CYP19 [9] CC 11 15 1 -
TT 17 7 OR 1.37 1.67 (1.00–2.81) 3.31 (1.02–10.72) 0.04*
TC 12 15 OR 1.26 1.05 (0.57–1.94) 1.09 (0.37–3.23) 0.55
TT or TC 29 22 0R 1.29 1.34 (0.81–2.23) 1.80 (0.69–4.67) 0.17
rs3834129 CASP 8 [10] nor/nor 8 9 1 -
del/del 12 6 HR 1.60 1.42 (0.78–2.58) 2.25 (0.57–8.82) 0.20
nor/del 19 23 HR 1.83 0.96 (0.53–1.76) 0.93 (0.30–2.88) 0.56
del/del or
nor/del
31 29 1.10 (0.63–1.92) 1.20 (0.41–3.54) 0.48
rs1045485 CASP 8 [11] GG 33 25 1 -
CC 1 6 HR 0.86 0.25 (0.04–1.56) 0.13 (0.01–1.12) 0.04*
GC 5 5 HR 0.83 0.88 (0.45–1.70) 0.76 (0.20─2.91) 0.47
CC or GC 6 11 0.62 (0.31─1.23) 0.41 (0.13─1.27) 0.10
rs2363956 9p13 ABHD8,
ANKLE1, C19orf62 [12]
AA 15 5 1 -
CC 7 13 HR 0.7 0.47 (0.24–0.89) 0.18 (0.05–0.70) 0.01*
AC 18 19 HR 0.89 0.65 (0.43–0.98) 0.32 (0.10–1.05) 0.05*
CC or AC 25 32 0.58 (0.40–0.86) 0.26 (0.08–0.81) 0.02*
rs16942 BRCA1 [13] TT 20 23 1 -
CC 5 9 HR 0.85 0.77 (0.35–1.66) 0.64 (0.18–2.22) 0.35
TC 15 6 1.54 (1.01–2.34) 2.88 (0.94–8.82) 0.05*
CC or TC 20 15 1.23 (0.80–1.89) 1.53 (0.62–3.77) 0.24
*: p < = 0.05
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mutations, of which 15 had young onset cancer. The ob-
served results and the calculated RRs, ORs and signifi-
cance levels are shown in Table 1, together with the
previously reported HRs and ORs [4–13]. All ten SNPs
tested showed point estimates of being positively or
negatively associated with having early onset breast can-
cer similar to previous reports. Because the references
had used different ways of ascertaining patients, includ-
ing different methods by which to calculate HRs and
ORs, we had no exact notion of what RRs and ORs
would be calculated for our study, and could not compute
theoretical significance levels against those expected.
We found that rs3803662 was significantly associated
with early onset breast cancer (p = 0.026 for heterozy-
gous cases and p = 0.040 for homo–or heterozygous
cases). The SNP rs10046 was positively associated with
early onset disease in the homozygous state (p = 0.040),
and rs104585 was negatively associated with early onset
breast cancer (p = 0.039 for homozygous). The SNP
rs2363956 was negatively associated with early cancer (p
= 0.012, p = 0.049 and p = 0.015 for homo-, hetero- or
homo- or heterozygous, respectively). Finally, rs16942
was significantly associated with early onset breast can-
cer (p = 0.05 for heterozygous). The distributions for
homozygous versus heterozygous for rs16942 were con-
flicting and remain to be precisely defined. The rs16942
SNP is within linkage distance from the BRCA1 gene,
and haplotyping of the patients/families in question may
be necessary to consider this further.
Discussion
In principle, we have confirmed the reported association
between the presence of variant SNPs and early onset of
breast cancer in BRCA1 mutation carriers. Five of the
SNPs tested revealed significant associations with early
ages of onset cancer, whereas five did not. The lack of
association may be due to different associations in the
Norwegian population compared to other populations,
which may be a result of genetic drift [18]. Also, stochas-
tic variation in our restricted number of patients may
have obscured the associations examined.
Sixty-three percent of the mutation carriers included
had one of the frequent Norwegian founder mutations,
in which we have determined the penetrance to be simi-
lar in retrospective series of extended pedigrees, which
we later confirmed through prospective studies of new
cases in the same families [18, 19]. There were no asso-
ciations with the presence of founder mutations or less
frequent mutations with early onset cancer. For this rea-
son, we do not have the confounder of putative different
penetrance of the causative mutations as discussed in
other reports [4–13]. This may be a third possible cause
for a stronger association in the Norwegian population.Yet another possible cause for the stronger associations
in our population is that we scored both breast and
ovarian cancer as affected phenotypes, while most re-
ports considered only breast cancer.
Also, most previous reports calculated HR from con-
tinuous distribution by other methods. The described dif-
ferences between the young cancer cases and the old no
cancer group might have been expected to show stronger
associations than those previously reported [4–13], due to
the methods applied, and not because of differences in the
populations studied.
We find that the limited number of cases in our study,
and some discrepancies between the previously reported
distribution between homozygous and heterozygous car-
riers in comparison to our findings, is likely to result in
insufficient power to evaluate the underlying mecha-
nisms of the associations observed. Our results may,
however, be considered to contribute towards a future
combined effort to precisely define the contribution of
risk provided by these polymorphisms. We would like to
add, however, that some of the discrepancies found may
not be methodological artifacts, but rather related to dif-
ferences in linkage disequilibrium between the SNPs
studied and disease in different populations. If this is
verified, the search for an actual risk value for the associ-
ation between breast cancer and the presence or absence
of a given SNP that is population specific may be a use-
ful approach in risk stratification. Some of the slight var-
iations in associations reported in the different
populations may have been caused by such mechanisms,
commonly referred to as genetic drift.
In conclusion, our validation gave similar, but not
identical results compared to those published by others.
Also, it is not currently established whether or not the
association to these SNPs are of clinical interest. We
have previously shown that BRCA1 carriers in our popu-
lation have on average 25 % risk of developing breast
cancer at 40 years of age [19]. The associations reported
here may give a ten percent higher or lower cancer risk
estimate at the time. Calculating the combined modify-
ing effects will apply to a very few cases, and the major-
ity will be close to 25 %. The clinical utility of the
findings is a question we leave open for discussion.
Through this report, we make the findings available for
BRCA1 mutation carriers in our population and for
international meta-analyses.Additional file
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